HIGHLIGHTS
- -Most statin treated patients do not achieve LDL-C therapeutic targets, remaining at high risk of CHD; the lost therapeutic benefit and the economic impact of delaying target achievement is unclear.
- -Delaying lipid-lowering intensification translates into worse health and economic outcomes compared to early and intense lipid lowering for statin treated individuals with uncontrolled LDL-C and no prior CVD.
ABSTRACT
Objective
Methods
Results
Conclusions
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Value in HealthArticle Info
Publication History
Publication stage
In Press Accepted ManuscriptFootnotes
Precis
Delaying lipid-intensification in statin treated patients yields suboptimal cost-effectiveness. This study shows utility of incorporating cumulative exposure to causal risk factors into health economic analysis.
Acknowledgements
N/A
Author contributions
Concept and design: Marquina, Morton, Zomer, Talic, Lybrand, Liew, Ademi
Analysis and interpretation of data: Marquina, Morton,
Drafting of the manuscript: Marquina, Lybrand,
Critical revision of the paper for important intellectual content: Marquina, Morton, Zomer, Talic, Thomson, Liew Ademi
Obtaining funding: Ademi
Supervision: Ademi
Conflict of Interest Disclosures
Dr Zomer reported receiving grants from Amgen, Astra Zeneca, Pfizer, and Shire, outside the submitted work. Dr Lybrand reported receiving other from Amgen (incl. subsidiaries), outside the submitted work; and is an employee of Amgen (incl. subsidiaries), which has medicines for use in cardiovascular conditions. Dr Thomson reported receiving other from Amgen (incl. subsidiaries), outside the submitted work; and is employed by Amgen Australia Pty Ltd. Dr Liew reported receiving grants and personal fees from Abbie, Amgen, Astra Zeneca, Pfizer, Bristol Myers-Squibb, Sanofi, outside the submitted work; and past participation in advisory boards of AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Edwards Lifesciences, Novartis, Pfizer, Sanofi, and Shire, outside the submitted work. No other disclosures were reported.
Funding/Support
This work was supported by the National Health and Medical Research Council Ideas Grants Application ID: 2012582.
